1. Introduction
The term interstitial lung disease (ILD) comprises a large group of diseases caused by chronic inflammation and fibrosis of the alveoli wall that share similar functional, clinical, radiological, and anatomopathological characteristics. ILDs can be classified according to their cause into idiopathic interstitial pneumonias (IIPs) or known cause ILDs [1,2,3]. Idiopathic pulmonary fibrosis (IPF) is the most frequent and severe IIP, characterized by a progressive dyspnea along with respiratory failure and a poor prognosis [4]. It is well known that the etiology of ILD is complex, and besides internal and external risk factors, a genetic component contributes to the development and severity of ILD [5]. The accurate diagnosis of these ILDs supposes a challenge for the clinicians and a multidisciplinary approach is frequently necessary [6].
The study of potential blood biomarkers in the pathogenesis of ILD is considered to be of potential interest, since they may be used as additional tools for the early diagnosis and severity prognosis of these pathologies. Furthermore, they are more reproducible and easier to obtain than conventional invasive methods of diagnosis [7,8,9].
Vascular endothelial growth factor (VEGF) is a tyrosine kinase glycoprotein that plays a key role as a mediator of angiogenesis and vasculogenesis in both physiological and pathological processes, being implicated in numerous inflammatory and chronic conditions [10,11,12,13,14,15,16,17,18]. In particular, it is well known that VEGF contributes to the normal lung maintenance, repair of pulmonary circulation, and modulation of the angiogenic process mainly related to endothelial cells [19,20,21]. In this line, some VEGF functional polymorphisms have been shown to influence the susceptibility to several lung disorders such as pulmonary hypertension and chronic obstructive pulmonary disease (COPD), among others [22,23,24,25,26]. However, studies on the genetic role of VEGF in ILD are scarce although VEGF protein levels have been proposed as a potential prognostic biomarker in IPF [7,18,27,28]. In fact, nintedanib, a tyrosine kinase inhibitor of VEGF receptors along with other signaling pathways, is one of the main drugs approved for the treatment of IPF [29].
Given that lung inflammation, altered fibrosis, and aberrant angiogenesis are typical processes in ILD pathogenesis, it is plausible to think that VEGF is implicated in ILD. Therefore, in this study we aimed to assess, for the first time, the role of VEGF polymorphisms in the susceptibility and severity of ILD in a large cohort of Caucasian patients with this disease.
2. Materials and Methods
2.1. Patients and Controls
A total of 436 Caucasian patients with ILD, fulfilling the American Thoracic Society/European Respiratory Society classification and diagnosis criteria for ILD [2,4,30] were recruited between May 2016 and December 2019 from the following referral Spanish hospitals: Hospital Universitario Marqués de Valdecilla (Santander), Hospital Puerta de Hierro and Hospital 12 de Octubre (Madrid), Hospital Universitario Vall d’Hebrón (Barcelona), and Hospital Universitario y Politécnico de la Fe (Valencia). Information on pulmonary function tests (PFTs) was collected from all the patients. Specifically, forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and diffusing capacity of the lungs for carbon monoxide (DLCO) were recorded at the time of recruitment. The whole cohort of patients with ILD was composed of 244 patients with IIP and 192 with known cause ILD (called non-IIP patients from now on). In particular, the group of IIP included mainly patients with IPF as well as patients with fibrotic idiopathic nonspecific interstitial pneumonia and unclassifiable IIPs, according to Cottin et al.’s classification [3]. The group of non-IIP was made up of the following categories: Patients with autoimmune ILDs, hypersensitivity pneumonitis, fibrosing pulmonary sarcoidosis, and other ILDs [3]. Demographic and clinical characteristics of the whole cohort of ILD patients, IIP patients, and non-IIP patients are shown in Table 1. In addition, the features of the non-IIP patients stratified according to the categories above mentioned are shown in Supplementary Table S1.
Five hundred and thirty-six ethnically-matched healthy controls, without a history of any pulmonary or chronic inflammatory disease, from Hospital Universitario Marqués de Valdecilla (Santander) and National DNA Bank Repository (Salamanca), were also included in this study.
All patients with ILD and healthy controls gave their informed consent to be included in the study. The procedures followed were in accordance with the ethical standards of the approved guidelines and regulations, according to the Declaration of Helsinki. All experimental protocols were approved by the local ethics committees of each participant hospital.
2.2. VEGF Polymorphisms Selection and Genotyping
VEGF polymorphisms were selected based on the following criteria: Polymorphisms with a frequency >5% in Caucasians previously assessed and reported to be involved in susceptibility to several inflammatory and pulmonary diseases [13,15,22,23,24,25,31]; functional polymorphisms associated with VEGF protein production [13,32]; and polymorphisms distributed along the gene. Accordingly, VEGF rs833061 and rs1570360 located in the VEGF promoter region, rs2010963 located in 5′untranslated region (UTR), rs3025020 located in intron 6, and rs3025039 located in 3′UTR of the VEGF gene were chosen.
Genomic DNA was extracted from peripheral blood using the REALPURE “SSS” kit (RBME04, REAL, Durviz S.L., Valencia, Spain). The quality and quantity of extracted DNA was measured in a spectrophotometer (NanoDrop ND-1000, Wilmington, DE, USA). All patients and healthy controls were genotyped for VEGF rs833061 T/C, rs1570360 G/A, rs2010963 G/C, rs3025020 C/T, and rs3025039 C/T polymorphisms by TaqMan assays. Negative controls and duplicate samples were included to check the accuracy of the genotyping. Genotyping was performed in a QuantStudioTM 7 Flex real-time polymerase chain reaction system (Applied Biosystems, Foster City, CA, USA).
2.3. Serum VEGF Determination
VEGF serum levels were determined in a subgroup of 272 ILD patients (133 IIP and 139 non-IIP) by a commercial ELISA kit (Reddot Biotech Inc., Kelowna, BC, Canada) in accordance with the manufacturer’s instructions. Samples were analyzed in duplicate. VEGF levels were quantified using a four-parameter logistic curve fit suitable for calculating concentrations from symmetrical sigmoidal calibrators through MyAssays software.
2.4. Statistical Analysis
Data were reported as the number of individuals (n) and percentage (%) for categorical variables and mean ± standard deviation (SD) for continuous variables. All genotype data were checked for deviation from Hardy–Weinberg equilibrium (HWE). For the estimation of allele frequencies, the number of individuals was duplicated considering that each individual carries 2 alleles of each polymorphism (one allele in each chromosome). Differences in VEGF genotypes, alleles, and carriers of the minor allele frequencies between the whole group of ILD patients and controls were calculated and compared by a chi-square test. Similarly, genetic differences between IIP patients and the whole group of non-IIP patients as well as between IIP patients and the different categories of the group of non-IIP patients (autoimmune ILDs, hypersensitivity pneumonitis, other ILDs and sarcoidosis) were assessed. Additionally, differences in the frequency of VEGF polymorphisms were analyzed between ILD patients and controls as well as between the group of patients with IIP and non-IIP patients, stratifying the population according to sex. Haplotype frequencies were calculated by the Haploview 4.2 software and then, compared between the groups mentioned above by a chi-square test. Strength of associations was estimated using odds ratios (OR) and 95% confidence intervals (CI). OR and p-values were adjusted by sex, age, smoking history, and packs of cigarettes per year when genetic differences between IIP and non-IIP patients were evaluated. Analyses regarding the association between VEGF and PFTs or VEGF serum levels in IIP and non-IIP patients were performed with carriers, given that the frequency of the TT genotype of rs3025039 was lower than 5%. These associations were assessed by linear regression, adjusting p-values for the potential confounding factors previously mentioned. In addition, to account for the five polymorphisms assessed, the Bonferroni adjustment was applied. Consequently, p-values < 0.01 were considered statistically significant. All statistical analyses were performed with STATA statistical software 12/SE (Stata Corp., College Station, TX, USA).
Estimations of statistical power were obtained with CaTS Power Calculator for Genetic Studies software (Supplementary Tables S2 and S3).
3. Results
3.1. Analysis of VEGF Genotype, Allele and Carrier Frequencies
The rs833061, rs1570360, rs2010963, rs3025020, and rs3025039 genotype distribution was in HWE. The genotyping success rate was 98.7% for rs833061, 97.9% for rs1570360, 99.1% for rs2010963, 98.6% for rs3025020, and 99.3% for rs3025039. Genotype and allele frequencies were in agreement with the data of the 1000 Genomes Project for Europeans.
Genotype, allele, and carrier frequencies of VEGF between the whole cohort of patients with ILD and healthy controls were compared. As shown in Table 2, no statistically significant differences in the frequencies of each VEGF polymorphism were found between these groups.
We also assessed the differences in VEGF frequencies between the group of patients with IIP and non-IIP patients. In this regard, no statistically significant differences in the genotype, allele, or carrier frequencies of each VEGF polymorphism were disclosed between them (Table 3). Likewise, no genetic differences were detected when IIP patients were compared to the group of non-IIP stratified into patients with autoimmune ILDs, hypersensitivity pneumonitis, sarcoidosis, and other ILDs (Supplementary Table S4).
When stratified by sex, no statistically significant differences in the genotype, allele, or carrier frequencies of each VEGF polymorphism were disclosed between the whole cohort of ILD patients and healthy controls (Supplementary Table S5). However, the frequency of the minor allele of VEGF rs1570360 was increased in women with IIP compared to women with non-IIP (38.0% versus 21.3%, OR = 2.26 [1.27–4.02], p = 0.005, Supplementary Table S6).
3.2. Haplotype Analysis of VEGF
Haplotype analysis showed five common haplotypes with a frequency greater than 5% both in healthy controls and ILD patients (Table 4). VEGF haplotypes’ frequencies were similar between the whole cohort of patients with ILD and healthy controls and no statistically significant differences were disclosed (Table 4). It was also the case when haplotypes’ frequencies were compared between IIP and non-IIP patients (Table 4).
3.3. Association of VEGF Polymorphisms with Pulmonary Function Tests
Since deterioration of PFTs generally indicates a worse outcome of the ILD, in a further step we determined whether VEGF polymorphisms influenced on PFTs in the whole group of patients with IIP and non-IIP. Interestingly, a decrease of FEV1 (% predicted) and DLCO (% predicted) was observed in IIP patients carrying the minor allele A of rs1570360 compared to non-carriers: 69.41 ± 22.34 versus 76.44 ± 21.88 for FEV1 and 32.07 ± 14.34 versus 38.30 ± 15.03 for DLCO, p = 0.004 and p = 0.008, respectively (Figure 1). No further associations between VEGF polymorphisms and PFTs were found in IIP or non-IIP patients (Supplementary Table S7).
3.4. Influence of VEGF Polymorphisms on VEGF Serum Levels
Finally, the influence of VEGF polymorphisms on VEGF serum levels in IIP and non-IIP patients was assessed. Similar VEGF serum levels were observed in IIP and non-IIP patients, regardless of the VEGF polymorphism assessed (Supplementary Table S8).
4. Discussion
It is widely known that biomarkers involved in the pathogenesis of ILD are considered as potential targets for therapy [7,8]. In this regard, there is a growing interest in the role of VEGF in the pathogenesis of ILD [18]. Consequently, we aimed to evaluate the role of five functional VEGF polymorphisms in the susceptibility and severity of ILD in a large cohort of patients.
In our study, the genotype, allele, and carrier frequencies of rs833061, rs1570360, rs2010963, rs3025020, and rs3025039 were similar between the whole cohort of patients with ILD and healthy controls as well as between IIP and non-IIP patients. Considering that the five polymorphisms assessed are located in relevant regions along the VEGF gene, based on our results it is reasonable to think that VEGF does not seem to be implicated in ILD. Of note, after conducting a literature review, we noticed that information on the potential role of VEGF polymorphisms in the susceptibility and severity of ILD was limited to a single study that only assessed rs2010963 in 60 IPF patients and 60 controls. In this study no association was found between VEGF and IPF [33], in keeping with our obtained data. Our results are also in accordance with those reported in other diseases. In particular, no genetic differences of rs699947 (in complete linkage disequilibrium with rs833061, r2 = 0.98, and D′ = 0.99 in European Population) and rs1570360 between patients with COPD and controls were also reported [31]. Likewise, no association with rs1570360 and rs2010963 polymorphisms was observed in rheumatoid arthritis, a chronic inflammatory disease that can be associated with ILD [34,35]. Additionally, haplotype analyses that provide a more comprehensive picture of the implication of a gene in a disease were performed in the present study to uncover hidden signals in the VEGF gene. In this regard, there were no significant differences in VEGF haplotype frequencies between the whole cohort of patients with ILD and healthy controls as well as between IIP and non-IIP patients, further supporting our findings obtained when polymorphisms were tested individually. Therefore, although VEGF is a potent angiogenic factor associated with pulmonary and chronic inflammatory diseases, our results suggest that it has no influence as a genetic biomarker for the susceptibility of ILD and for the differential diagnosis between the different diseases encompassed under the term ILD. Nevertheless, we disclosed a sex-specific association of the minor allele of VEGF rs1570360 with an increased risk of IIP in women. In this line, a gender-specific association with rs1570360 and other VEGF polymorphisms has been previously described in women with other non-pulmonary diseases [36,37,38,39]. However, the potential relevance of rs1570360 as a marker of IIP in women should be interpreted with caution considering that the frequency of women with IIP in our population was relatively low. In this sense, we feel that a replication study using an independent cohort of patients with IIP is required to confirm our data.
Regarding the influence of VEGF polymorphisms on PFTs, we disclosed, for the first time, a potential association of rs1570360 with a worse lung function in IIP patients. In particular, a significant decrease in FEV1 and DLCO was observed, which may suggest that rs1570360 influences airway function. It is worth mentioning that other VEGF polymorphisms were also reported to be associated with an altered lung function in patients with COPD and asthma [23,26]. Further studies on this issue are needed to confirm the role of VEGF in lung function.
Finally, we determined whether the VEGF polymorphisms assessed may affect VEGF serum levels in ILD patients. However, none of the VEGF polymorphisms were associated with VEGF levels in IIP or non-IIP patients. Likewise, Baz–Dávila et al. reported a lack of association between rs833070 (in complete linkage disequilibrium with rs833061, r2 = 0.98, and D′ = 0.99 in European Population) and rs3025020 with VEGF serum levels in Spanish patients with COPD [23]. In addition, rs1570360, rs2010963, and rs3025039 were not related with VEGF serum levels in patients with inflammatory bowel disease [13]. In accordance with these findings, our results support the hypothesis that the regulation of VEGF serum levels may depend on local and systemic inflammatory changes accompanying the disease, rather than on genetic factors, as previously claimed by Almawy et al. [32].
In conclusion, our results do not support a relevant role of VEGF in ILD. Nevertheless, they suggest that rs1570360 could be a marker of severity of ILD in women and may indicate a worse outcome in patients with IIP.
Supplementary Materials
The following are available online at
Author Contributions
Conceptualization, S.R.-M., F.G., and V.P.-C.; data curation, S.R.-M., F.G., V.P.-C., B.A.-M., V.M.M.C., D.I.F., S.M.F.R., L.L.-G., P.A.L., M.P.U., R.L., C.B., A.S., V.P., A.D.P.G., O.G., and J.M.C.; formal analysis, S.R.-M., F.G., and V.P.-C.; investigation, S.R.-M., F.G., V.P.-C., B.A.-M., V.M.M.C., D.I.F., S.M.F.R., L.L.-G., P.A.L., M.P.U., R.L., C.B., A.S., V.P., A.D.P.G., O.G., and J.M.C.; methodology, S.R.-M., F.G., and V.P.-C.; project administration, R.L.-M. and M.Á.G.-G.; supervision, R.L.-M. and M.Á.G.-G.; visualization, S.R.-M., F.G., and V.P.-C.; writing—original draft, S.R.-M., F.G., and V.P.-C.; writing—review and editing, S.R.-M., F.G., V.P.-C., R.L.-M., and M.Á.G.-G. All authors have read and agreed to the published version of the manuscript.
Funding
This research was partially supported by a grant from Spanish Society of Pulmonology and Thoracic Surgery (SEPAR 474-2017). S.R.-M. was supported by funds of the RETICS Program (RD16/0012/0009) from the “Instituto de Salud Carlos III” (ISCIII), co-funded by the European Regional Development Fund. V.P.-C. was supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). B.A.-M. was recipient of a “López Albo” post-residency program funded by Servicio Cántabro de Salud. L.L.-G. was supported by funds from IDIVAL (INNVAL 20/06). O.G. was beneficiary of a grant funded by Xunta de Galicia, Consellería de Educación, Universidade e Formación Profesional and Consellería de Economía, Emprego e Industria (GAIN), GPC IN607B2019/10. R.L.-M. was a recipient of a Miguel Servet type I program fellowship from the ISCIII, co-funded by the ESF, “Investing in your future” (grant CP16/00033).
Institutional Review Board Statement
All subjects gave their informed consent to be included in the study. The procedures followed were in accordance with the ethical standards of the approved guidelines and regulations, in accordance with the Declaration of Helsinki. All experimental protocols were approved by the local ethics committees of each participant hospital (protocol code 12/2016 and date of approval 01/07/2016).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
All data generated or analyzed during this study are included in this published article.
Acknowledgments
We wish to thank all the patients and controls for their essential collaboration to this study. We would also like to specially thank Verónica Mijares for her technical assistance.
Conflicts of Interest
The authors declare no conflict of interest related to this study.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figure and Tables
Enlarge this image.Figure 1. Decrease of forced expiratory volume in one second (FEV1) and diffusing capacity of the lungs for carbon monoxide (DLCO) in patients with idiopathic interstitial pneumonia carrying the minor allele A of VEGF rs1570360. Horizontal lines in box plots indicate the mean value of each study group. p-values were adjusted by sex, age, smoking history, and packs of cigarettes per year.
Demographic and clinical characteristics of the 436 patients with ILD included in this study.
| Characteristic | Whole Cohort of ILD Patients |
IIP Patients |
Non-IIP Patients |
|---|---|---|---|
| Sex (men/women), n (%) | 294/142 (67.4/32.6) | 190/54 (77.9/22.1) | 104/88 (54.2/45.8) |
| Age at the time of the study (years), mean ± SD | 61.1 ± 10.2 | 62.8 ± 9.4 | 59.0 ± 10.8 |
| Smoking history, n (%) | 294 (69.2) | 178 (74.2) | 116 (62.7) |
| Packs of cigarettes per year, mean ± SD | 30.7 ± 20.2 | 33.8 ± 20.7 | 25.8 ± 18.5 |
| Pulmonary function tests | |||
| FVC (% predicted), mean ± SD | 76.8 ± 24.1 | 73.0 ± 22.7 | 81.7 ± 25.0 |
| FEV1 (% predicted), mean ± SD | 73.7 ± 23.6 | 72.8 ± 22.4 | 74.8 ± 25.0 |
| DLCO (% predicted), mean ± SD | 36.4 ± 15.7 | 35.2 ± 15.0 | 37.9 ± 16.6 |
DLCO: Diffusing capacity of the lungs for carbon monoxide; FEV1: Forced expiratory volume in one second; FVC: Forced vital capacity; IIP: Idiopathic interstitial pneumonia; ILD: Interstitial lung disease; SD: Standard deviation.
Table 2Genotype, allele, and carrier frequencies of VEGF polymorphisms in ILD patients and controls included in this study.
| VEGF Polymorphism | Genotype/Allele/ |
Whole Cohort of ILD Patients |
Healthy Controls |
OR [95% CI] | p-Value |
|---|---|---|---|---|---|
| rs833061 | TT | 32.6 (142/435) | 28.8 (151/524) | Reference | - |
| TC | 47.6 (207/435) | 48.7 (255/524) | 0.86 [0.64–1.16] | 0.33 | |
| CC | 19.8 (86/435) | 22.5 (118/524) | 0.78 [0.54–1.11] | 0.17 | |
| T | 56.4 (491/870) | 53.1 (557/1048) | Reference | - | |
| C | 43.6 (379/870) | 46.9 (491/1048) | 0.88 [0.73–1.05] | 0.15 | |
| C non-carriers | 32.6 (142/435) | 28.8 (151/524) | Reference | - | |
| C carriers | 67.4 (293/435) | 71.2 (373/524) | 0.84 [0.63–1.10] | 0.20 | |
| rs1570360 | GG | 53.5 (232/434) | 48.3 (250/518) | Reference | - |
| GA | 38.0 (165/434) | 41.9 (217/518) | 0.82 [0.63–1.07] | 0.15 | |
| AA | 8.5 (37/434) | 9.8 (51/518) | 0.78 [0.49–1.24] | 0.29 | |
| G | 72.5 (629/868) | 69.2 (717/1036) | Reference | - | |
| A | 27.5 (239/868) | 30.8 (319/1036) | 0.85 [0.70–1.04] | 0.12 | |
| A non-carriers | 53.5 (232/434) | 48.3 (250/518) | Reference | - | |
| A carriers | 46.5 (202/434) | 51.7 (268/518) | 0.81 [0.63–1.05] | 0.11 | |
| rs2010963 | GG | 43.0 (187/435) | 43.7 (231/528) | Reference | - |
| GC | 43.2 (188/435) | 46.6 (246/528) | 0.94 [0.72–1.24] | 0.68 | |
| CC | 13.8 (60/435) | 9.7 (51/528) | 1.45 [0.95–2.21] | 0.08 | |
| G | 64.6 (562/870) | 67.0 (708/1056) | Reference | - | |
| C | 35.4 (308/870) | 33.0 (348/1056) | 1.11 [0.92–1.35] | 0.26 | |
| C non-carriers | 43.0 (187/435) | 43.7 (231/528) | Reference | - | |
| C carriers | 57.0 (248/435) | 56.3 (297/528) | 1.03 [0.80–1.33] | 0.81 | |
| rs3025020 | CC | 51.9 (225/434) | 54.4 (285/524) | Reference | - |
| CT | 39.6 (172/434) | 37.0 (194/524) | 1.12 [0.86–1.47] | 0.40 | |
| TT | 8.5 (37/434) | 8.6 (45/524) | 1.04 [0.65–1.66] | 0.87 | |
| C | 71.7 (622/868) | 72.9 (764/1048) | Reference | - | |
| T | 28.3 (246/868) | 27.1 (284/1048) | 1.06 [0.87–1.30] | 0.55 | |
| T non-carriers | 51.8 (225/434) | 54.4 (285/524) | Reference | - | |
| T carriers | 48.2 (209/434) | 45.6 (239/524) | 1.11 [0.86–1.43] | 0.43 | |
| rs3025039 | CC | 74.5 (325/436) | 79.0 (418/529) | Reference | - |
| CT | 22.7 (99/436) | 18.9 (100/529) | 1.27 [0.93–1.73] | 0.13 | |
| TT | 2.8 (12/436) | 2.1 (11/529) | 1.40 [0.61–3.22] | 0.42 | |
| C | 85.9 (749/872) | 88.5 (936/1058) | Reference | - | |
| T | 14.1 (123/872) | 11.5 (122/1058) | 1.26 [0.96–1.65] | 0.09 | |
| T non-carriers | 74.5 (325/436) | 79.0 (418/529) | Reference | - | |
| T carriers | 25.5 (111/436) | 21.0 (111/529) | 1.29 [0.95–1.74] | 0.10 |
CI: Confidence interval; ILD: Interstitial lung disease; N: Total number of individuals successfully genotyped; OR: Odds ratio; VEGF: Vascular endothelial growth factor.
Table 3Genotype, allele, and carrier frequencies of VEGF polymorphisms in IIP and non-IIP patients included in this study.
| VEGF Polymorphism | Genotype/Allele/ |
IIP Patients |
Non-IIP Patients |
OR [95% CI] * | p-Value * |
|---|---|---|---|---|---|
| rs833061 | TT | 28.7 (70/244) | 37.7 (72/191) | Reference | - |
| TC | 49.2 (120/244) | 45.6 (87/191) | 1.32 [0.82–2.11] | 0.25 | |
| CC | 22.1 (54/244) | 16.7 (32/191) | 1.73 [0.95–3.16] | 0.07 | |
| T | 53.3 (260/488) | 60.5 (231/382) | Reference | - | |
| C | 46.7 (228/488) | 39.5 (151/382) | 1.33 [0.99–1.79] | 0.06 | |
| C non-carriers | 28.7 (70/244) | 37.7 (72/191) | Reference | - | |
| C carriers | 71.3 (174/244) | 62.3 (119/191) | 1.43 [0.92–2.22] | 0.12 | |
| rs1570360 | GG | 47.5 (116/244) | 61.1 (116/190) | Reference | - |
| GA | 43.4 (106/244) | 31.1 (59/190) | 1.79 [1.14–2.81] | 0.01 | |
| AA | 9.1 (22/244) | 7.8 (15/190) | 1.50 [0.68–3.31] | 0.31 | |
| G | 69.3 (338/488) | 76.6 (291/380) | Reference | - | |
| A | 30.7 (150/488) | 23.4 (89/380) | 1.46 [1.04–2.05] | 0.03 | |
| A non-carriers | 47.5 (116/244) | 61.1 (116/190) | Reference | - | |
| A carriers | 52.5 (128/244) | 38.9 (74/190) | 1.74 [1.14–2.65] | 0.01 | |
| rs2010963 | GG | 44.7 (109/244) | 40.8 (78/191) | Reference | - |
| GC | 42.2 (103/244) | 44.5 (85/191) | 0.80 [0.51–1.25] | 0.32 | |
| CC | 13.1 (32/244) | 14.7 (28/191) | 0.66 [0.34–1.25] | 0.20 | |
| G | 65.8 (321/488) | 63.1 (241/382) | Reference | - | |
| C | 34.2 (167/488) | 36.9 (141/382) | 0.80 [0.59–1.08] | 0.15 | |
| C non-carriers | 44.7 (109/244) | 40.8 (78/191) | Reference | - | |
| C carriers | 55.3 (135/244) | 59.2 (113/191) | 0.76 [0.50–1.16] | 0.20 | |
| rs3025020 | CC | 50.4 (123/244) | 53.7 (102/190) | Reference | - |
| CT | 39.8 (97/244) | 39.5 (75/190) | 1.13 [0.73–1.76] | 0.57 | |
| TT | 9.8 (24/244) | 6.8 (13/190) | 1.57 [0.69–3.54] | 0.28 | |
| C | 70.3 (343/488) | 73.4 (279/380) | Reference | - | |
| T | 29.7 (145/488) | 26.6 (101/380) | 1.20 [0.86–1.67] | 0.28 | |
| T non-carriers | 50.4 (123/244) | 53.7 (102/190) | Reference | - | |
| T carriers | 49.6 (121/244) | 46.3 (88/190) | 1.20 [0.79–1.82] | 0.40 | |
| rs3025039 | CC | 77.5 (189/244) | 70.8 (136/192) | Reference | - |
| CT | 20.5 (50/244) | 25.5 (49/192) | 0.63 [0.38–1.04] | 0.07 | |
| TT | 2.0 (5/244) | 3.7 (7/192) | 1.09 [0.24–5.02] | 0.91 | |
| C | 87.7 (428/488) | 83.6 (321/384) | Reference | - | |
| T | 12.3 (60/488) | 16.4 (63/384) | 0.72 [0.47–1.12] | 0.14 | |
| T non-carriers | 77.5 (189/244) | 70.8 (136/192) | Reference | - | |
| T carriers | 22.5 (55/244) | 29.2 (56/192) | 0.66 [0.41–1.06] | 0.09 |
* OR (95% CI) and p-values were adjusted by sex, age, smoking history, and packs of cigarettes per year. CI: confidence interval; IIP: Idiopathic interstitial pneumonia; N: Total number of individuals successfully genotyped; OR: Odds ratio; VEGF: Vascular endothelial growth factor.
Table 4Haplotype differences of VEGF between the whole group of patients with ILD and healthy controls, and between IIP and non-IIP patients.
| Whole Cohort of ILD Patients versus Controls | IIP versus Non-IIP Patients | |||||||
|---|---|---|---|---|---|---|---|---|
| Haplotype * | Frequency in ILD |
Frequency in Controls |
OR [95% CI] | p-Value | Frequency in IIP |
Frequency in Non-IIP |
OR [95% CI] ‡ | p-Value ‡ |
| TGGCC | 31.4 (271/862) | 32.6 (330/1012) | Reference | - | 30.7 (150/488) | 32.4 (121/374) | Reference | - |
| TGCCC | 10.7 (92/862) | 9.8 (99/1012) | 1.13 [0.82–1.57] | 0.46 | 10.0 (49/488) | 11.5 (43/374) | 0.81 [0.48–1.36] | 0.42 |
| CAGCC | 7.1 (61/862) | 9.3 (94/1012) | 0.79 [0.55–1.13] | 0.20 | 7.8 (38/488) | 6.2 (23/374) | 1.11 [0.60–2.05] | 0.74 |
| CGGCC | 7.5 (65/862) | 7.7 (78/1012) | 1.01 [0.70–1.46] | 0.94 | 8.6 (42/488) | 6.2 (23/374) | 1.56 [0.86–2.86] | 0.15 |
| CAGTC | 8.1 (70/862) | 7.6 (77/1012) | 1.11 [0.77–1.59] | 0.58 | 9.4 (46/488) | 6.4 (24/374) | 1.67 [0.92–3.05] | 0.09 |
* The polymorphism order was rs833081, rs1570360, rs2010963, rs3025020, and rs3025039. ‡ OR 95% CI and p-values were adjusted by sex, age, smoking history, and packs of cigarettes per year. CI: Confidence interval; IIP: Idiopathic interstitial pneumonia; ILD: Interstitial lung disease; N: Total number of individuals successfully genotyped; OR: Odds ratio; VEGF: Vascular endothelial growth factor.
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
; Genre, Fernanda 1
; Pulito-Cueto, Verónica 1
; Atienza-Mateo, Belén 2
; Mora Cuesta, Víctor Manuel 3
; David Iturbe Fernández 3
; Fernández Rozas, Sonia María 3 ; Lera-Gómez, Leticia 1 ; Pilar Alonso Lecue 3 ; María Piedad Ussetti 4 ; Laporta, Rosalía 4 ; Berastegui, Cristina 5
; Solé, Amparo 6 ; Pérez, Virginia 7 ; Alicia De Pablo Gafas 7 ; Gualillo, Oreste 8
; Cifrián, José Manuel 9 ; López-Mejías, Raquel 1
; González-Gay, Miguel Ángel 10
1 Genetic epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, 39011 Santander, Spain;
2 Genetic epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, 39011 Santander, Spain;
3 Genetic epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, 39011 Santander, Spain;
4 Pneumology Department, Hospital Universitario Puerta de Hierro, 28222 Majadahonda, Spain;
5 Pneumology Department, Hospital Universitario Vall d’Hebron, Universidad Autónoma de Barcelona, 08035 Barcelona, Spain;
6 Lung Transplant and Cystic Fibrosis Unit, Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain;
7 Lung Transplant Unit, Division of Pulmonology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain;
8 SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab. (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago University Clinical Hospital, 15706 Santiago de Compostela, Spain;
9 Genetic epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, 39011 Santander, Spain;
10 Genetic epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, 39011 Santander, Spain;